[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

AbCellera's ABCL635 Phase One Data Could Redefine What Investors Are Actually Owning Here

AbCellera Biologics (NASDAQ: ABCL) reports first-quarter 2026 earnings after the close on Monday, May 11, 2026, with analysts expecting another quarterly loss as the antibody discovery platform company navigates a challenging revenue environment. The central question: can ABCL demonstrate progress in rebuilding its partnership pipeline and stabilizing revenue after last quarter's surprise beat, or will the sharp sequential revenue decline analysts are forecasting signal deeper structural headwinds? With the stock up sharply in recent weeks and trading well above all major moving averages, the technical setup suggests investors are pricing in optimism—making the actual results and forward guidance critical to...

Fundamentals

See More
  • Market Capitalization, $K 1,599,589
  • Shares Outstanding, K 305,265
  • Annual Sales, $ 75,130 K
  • Annual Income, $ -146,410 K
  • EBIT $ -195 M
  • EBITDA $ -166 M
  • 60-Month Beta 1.02
  • Price/Sales 19.58
  • Price/Cash Flow N/A
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 92.09% (+4.03%)
  • Historical Volatility 60.59%
  • IV Percentile 24%
  • IV Rank 9.70%
  • IV High 335.35% on 02/04/26
  • IV Low 65.96% on 05/09/25
  • Expected Move (DTE 4) 0.72 (13.79%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 8,167
  • Volume Avg (30-Day) 4,232
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 71,575
  • Open Int (30-Day) 65,429
  • Expected Range 4.52 to 5.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 2
  • High Estimate $-0.20
  • Low Estimate $-0.24
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) -46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.37 +55.49%
on 04/09/26
5.25 -0.19%
on 05/08/26
+1.81 (+52.77%)
since 04/08/26
3-Month
2.93 +78.84%
on 02/12/26
5.25 -0.19%
on 05/08/26
+2.08 (+65.82%)
since 02/06/26
52-Week
1.94 +170.10%
on 05/23/25
6.51 -19.57%
on 10/08/25
+3.23 (+160.70%)
since 05/08/25

Most Recent Stories

More News
AbCellera's ABCL635 Phase One Data Could Redefine What Investors Are Actually Owning Here

Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...

ABCL : 5.24 (+8.71%)
AbCellera's ABCL635 Phase One Data Could Redefine What Investors Are Actually Owning Here

Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...

ABCL : 5.24 (+8.71%)
AbCellera's ABCL635 Phase One Data Could Redefine What Investors Are Actually Owning Here

Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...

ABCL : 5.24 (+8.71%)
AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026...

ABCL : 5.24 (+8.71%)
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic...

ABCL : 5.24 (+8.71%)
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera (Nasdaq: ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)...

ABCL : 5.24 (+8.71%)
AbCellera Reports Full Year 2025 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. ...

ABCL : 5.24 (+8.71%)
3 New Stocks SoftBank Is Betting Big on in 2026

SoftBank revealed new positions in each of these three companies.

TMUS : 193.63 (-0.29%)
NVDA : 215.20 (+1.75%)
ABCL : 5.24 (+8.71%)
$SPX : 7,398.93 (+0.84%)
CRCL : 113.67 (+0.37%)
XXI : 8.62 (+3.11%)
SFTBY : 20.1500 (+4.84%)
^BTCUSD : 81,073.71 (+1.19%)
AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4,...

ABCL : 5.24 (+8.71%)
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)...

ABCL : 5.24 (+8.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 5.74
2nd Resistance Point 5.49
1st Resistance Point 5.37
Last Price 5.24
1st Support Level 5.00
2nd Support Level 4.75
3rd Support Level 4.63

See More

52-Week High 6.51
Last Price 5.24
Fibonacci 61.8% 4.77
Fibonacci 50% 4.23
Fibonacci 38.2% 3.69
52-Week Low 1.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.